Investigational drug · Phase 2
ORKA-002
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Plaque Psoriasis, Hidradenitis Suppurativa (HS).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "ORKA-002"
First trial start
2026
Mar 19, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ORKA-002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Plaque Psoriasis
- Hidradenitis Suppurativa (HS)
Approved drugs for the same conditions: Plaque psoriasis · Hidradenitis suppurativa · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "ORKA-002" as an intervention, largest first.
- ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis SuppurativaPivotal-lookingRecruiting
Oruka Therapeutics, Inc.Industry
NCT07783542 · 200 participants (planned) · Start Aug 21, 2026 · Primary completion Oct 2028
Drug: ORKA-002 · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Fountain Valley, California; Los Angeles, California · 25 sites in all
- An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque PsoriasisEnrolling by invitation
Oruka Therapeutics, Inc.Industry
NCT07933783 · 160 participants (planned) · Start Oct 26, 2026 · Primary completion Jul 1, 2029
Drug: ORKA-002 · For: Plaque Psoriasis
Sites: Fountain Valley, California; Milford, Massachusetts; New Brighton, Minnesota · 8 sites in all
- Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque PsoriasisPivotal-lookingActive, not recruiting
Oruka Therapeutics, Inc.Industry
NCT07474792 · 160 participants (planned) · Start Mar 19, 2026 · Primary completion Oct 2027
Drug: ORKA-002 · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Fountain Valley, California · 40 sites in all
- ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single DoseCompleted
Oruka Therapeutics, Inc.Industry
NCT06944379 · 24 participants · Start May 19, 2025 · Primary completion Aug 20, 2026
Drug: ORKA-002 · For: Healthy Volunteers
Sites: Christchurch, New Zealand
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Plaque Psoriasis
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- EnvudeucitinibPhase 34 trials
Alumis Inc · Plaque Psoriasis, SLE
- ICP-332Phase 34 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Non Segmental Vitiligo, Chronic Spontaneous Urticaria (CSU), Atopic Dermatitis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- NetakimabPhase 32 trials
Biocad · Plaque Psoriasis
- PicankibartPhase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriatic Arthritis, Plaque Psoriasis
- piclidenosonPhase 32 trials
Can-Fite BioPharma · Plaque Psoriasis, Lowe Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.